Abstract
Background and study aim: New therapeutic choices have been developed for hepatocellular carcinoma (HCC), including percutaneous ablation therapy, transarterial chemoembolization, radiation therapy and molecular target therapy. Ablation of liver tumors is currently the main alternative to formal liver resection. This work aimed at comparing percutaneous ethanol injection (PEI) with combined percutaneous ethanol and mitoxantrone injection (PIM) in treatment of HCC. Patients and methods: : This study included 125 patients with 131 HCC lesions which were randomly divided into two groups; group I composed of 68 lesions in 65 patients treated with PEI. Group II composed of 63 lesions in 60 patients treated with PEI and PIM. Clinical assessment, laboratory evaluation and CT studies were performed to all patients pre treatment and at 3, 6, and 12 months post treatment. Each focal lesion was considered as one subject. Results : : The percentage of ablation in both groups at 3, 6, 12 months were 60.3%, 48.5% and 39.7% in group I respectively versus 85.5%, 74.6% and 68% in group II respectively with a statistical significant difference between the two groups. There is an increased number of local recurrence in group I compared to group II. Side effects and complications are comparable in both groups. Conclusion : : Combination of PEI and PIM is better than PEI alone without additional complication and recurrence rate seemed to be better in combination therapy than PEI alone.
Highlights
Hepatocellular carcinoma (HCC) is a highly malignant cancer and it is the sixth most common cancer worldwide and the third most common cause of cancer related deaths with higher prevalence in Asia and sub-Saharan Africa [1].Advancement in diagnostic radiology and nuclear medicine contributed to the accurate and early diagnosis of hepatocellular carcinoma (HCC)
Percutaneous ethanol injection (PEI) is a procedure of easy execution, good tolerability and low cost, which can be applied in repeated sessions [2]
Ethanol induces immediate coagulative necrosis and injury thrombosis of tumor cells and enable the complete ablation of small neoplastic lesions without adversely affecting liver function.percutaneous ethanol injection (PEI) is a procedure of easy execution, good tolerability and low cost, which can be applied in repeated sessions [2] and that is why we used this maneuver for percutanous ablation in our low resource community
Summary
Hepatocellular carcinoma (HCC) is a highly malignant cancer and it is the sixth most common cancer worldwide and the third most common cause of cancer related deaths with higher prevalence in Asia and sub-Saharan Africa [1].Advancement in diagnostic radiology and nuclear medicine contributed to the accurate and early diagnosis of HCC. Experiences in interventional radiology, radiation oncology and surgery fields have grown, and new therapeutic choices have been developed including percutaneous ablation therapy, transarterial chemoembolization (TACE), radiation therapy and molecular target therapy[4]. New therapeutic choices have been developed for hepatocellular carcinoma (HCC), including percutaneous ablation therapy, transarterial chemoembolization, radiation therapy and molecular target therapy. This work aimed at comparing percutaneous ethanol injection (PEI) with combined percutaneous ethanol and mitoxantrone injection (PIM) in treatment of HCC. Patients and methods: This study included 125 patients with 131 HCC lesions which were randomly divided into two groups; group I composed of 68 lesions in 65 patients treated with PEI. Group II composed of 63 lesions in 60 patients treated with PEI and PIM. Conclusion: Combination of PEI and PIM is better than PEI alone without additional complication and recurrence rate seemed to be better in combination therapy than PEI alone
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
